Dr. Erica Schwartz enters the Senate Health, Education, Labor and Pensions Committee room today with the heaviest burden in modern public health history. The retired Navy Rear Admiral and former Deputy Surgeon General is President Donald Trump’s third attempt to place a permanent director at the helm of the Centers for Disease Control and Prevention. If confirmed, she inherits a federal agency hollowed out by political infighting, mass resignations, and a direct assault on its scientific foundation led by Health and Human Services Secretary Robert F. Kennedy Jr. Schwartz must thread an incredibly narrow needle: convincing a deeply skeptical Senate that she will protect scientific integrity while reassuring a hostile White House that she is a loyal team player.
She is the compromise candidate. Meanwhile, you can find related stories here: The Tehran Blackout Myth Why Iran Will Never Stop the Flow of Middle East Oil.
After eighteen months of administrative chaos, the CDC has operated without a Senate-confirmed leader for nearly a year. The vacancy is not a mere bureaucratic oversight; it is the direct result of an ongoing ideological war over the future of American medicine. While the agency sits in a holding pattern, public health emergencies are mounting. The country is currently facing an early and unusually aggressive West Nile virus season, localized outbreaks of measles, and a massive foodborne cyclosporiasis outbreak that has sickened thousands. Overseas, a deadly Ebola outbreak in the Democratic Republic of the Congo continues to threaten global security.
Schwartz’s hearing is not just an evaluation of her resume. It is a referendum on whether the nation's premier public health agency can survive the current administration's desire to dismantle it. To explore the bigger picture, we recommend the recent analysis by The New York Times.
A Rudderless Ship in the Middle of a Storm
The agency has been in near-constant turmoil. In March 2025, the administration’s first nominee, former Florida Representative Dave Weldon, saw his nomination collapse hours before his hearing when it became clear he lacked the votes to pass the committee. Weldon, a physician who had spent years amplifying thoroughly debunked claims linking childhood vaccines to autism, proved too extreme even for a Republican-controlled Senate.
Then came Susan Monarez. She was confirmed by the Senate, bringing a brief glimmer of stability to the agency’s Atlanta headquarters. That stability lasted less than a month. Monarez was abruptly fired after she refused to capitulate to demands from Health Secretary Robert F. Kennedy Jr. Insider reports revealed that Kennedy demanded Monarez hand over the keys to the childhood vaccine schedule, allowing political appointees to pre-approve recommendations before they were released to the public. Monarez refused. When she was forced out, four of the CDC’s top career scientists resigned in protest, leaving the agency’s senior ranks severely depleted.
The damage was immediate. Since then, the CDC has been run by a rotating cast of acting officials, none of whom possess the political capital or statutory authority to push back against the sweeping changes coming from HHS headquarters.
Under Kennedy’s direction, the Advisory Committee on Immunization Practices was completely restructured. The panel, which historically relied on rigorous peer-reviewed data to issue immunization guidelines used by insurance companies and pediatricians, began softening its recommendations for standard childhood vaccines. Earlier this year, the CDC bypassed its own internal scientific review boards to announce plans to scale back the number of universally recommended vaccines for children. Though a federal judge temporarily blocked the policy after a coalition of medical associations sued, the message was clear: science is no longer the sole driver of policy at HHS.
The Ghost of the Monarez Ouster
Schwartz’s career suggests she is a conventional, institutional pick. With nearly three decades of combined service in the Navy, Coast Guard, and the U.S. Public Health Service Commissioned Corps, she understands the machinery of government. During her tenure as Deputy Surgeon General, she managed the complex logistics of the federal vaccine distribution effort during the height of the COVID-19 pandemic.
She has no public record of anti-vaccine sentiment. To the public health establishment, this makes her a relief. To the ideologues advising the president, however, her conventionality is a risk.
Senators on both sides of the aisle will spend today demanding to know how Schwartz plans to handle the "Kennedy problem". If Kennedy demands that she alter scientific briefs or withdraw recommendations for life-saving therapeutics, will she stand her ground and risk the same fate as Monarez? Or will she bend to the political winds to keep her job?
Schwartz’s private-sector ties will also face scrutiny. Since leaving government in 2021, she has served as UnitedHealthcare’s president of insurance solutions for Medicare and retirement. UnitedHealthcare is the largest health insurer in the United States. While Schwartz has signed a strict ethics agreement promising to divest her healthcare holdings, step down from her corporate roles, and recuse herself from matters directly involving her former employer, progressives are wary. They worry that her recent years spent maximizing corporate insurance profits might influence how she directs an agency designed to serve the uninsured and vulnerable.
Two Nominees and Two Very Different Paths
The hearing is a split-screen affair. Sharing the hot seat with Schwartz is Sean Kaufman, the administration’s nominee to lead the Office of the Assistant Secretary for Preparedness and Response.
The contrast between the two nominees is stark. While Schwartz represents the traditional public health apparatus, Kaufman represents the populist, skeptical movement currently reshaping federal policy. Kaufman has previously raised eyebrows by publicly questioning the necessity of the hepatitis B vaccine for newborns, casting doubt on the safety of mRNA technology, and repeating disproven theories linking childhood immunizations to developmental disorders.
If confirmed, Kaufman will oversee the Strategic National Stockpile, the nation's repository of emergency medicines, vaccines, and medical supplies. The dynamic between Kaufman and Schwartz will dictate how the federal government responds to the next domestic health emergency. If a highly pathogenic strain of avian influenza begins spreading efficiently among humans, the CDC must work hand-in-hand with ASPR to coordinate the distribution of antivirals and candidate vaccines.
Yet, it is highly unclear how a traditionalist like Schwartz and a vaccine-skeptic like Kaufman can co-exist within the same leadership structure. The Senate committee will likely press both nominees on how they plan to reconcile their fundamentally opposing views of medicine when a crisis hits.
The Bill Cassidy Factor
The political theater inside the Dirksen Senate Office Building will be guided by Senator Bill Cassidy. Cassidy, a Louisiana Republican and a physician, chairs the HELP committee.
Cassidy occupies a unique political space. He lost his primary earlier this year after the president targeted him for retribution over his vote to convict Trump during the 2021 impeachment trial. With nothing left to lose politically, Cassidy has grown increasingly defiant. He has voiced deep skepticism regarding Kennedy’s sweeping plans to rewrite American vaccine guidelines.
Despite his opposition to the administration's broader healthcare agenda, Cassidy has signaled that he is receptive to Schwartz’s nomination. He met with her privately last month and publicly called her "very impressive".
Cassidy’s support is essential for Schwartz, but it comes with a catch. He is likely to use his line of questioning to force Schwartz into making explicit, on-the-record commitments to protect career scientists from political retaliation. For Schwartz, answering Cassidy’s questions too honestly could doom her standing with the White House before she even takes the oath of office. If she avoids giving direct answers, she risks losing the moderate Republicans and Democrats she needs to secure confirmation.
Rebuilding an Agency from the Inside Out
The administrative damage to the CDC goes far deeper than just a vacant director's suite. The mass firings and forced departures of 2025 have left the agency's morale at an all-time low.
Career scientists, epidemiologists, and lab technicians have left in droves, exhausted by constant public attacks and the feeling that their research is being filtered through an ideological lens. Many of the agency’s critical divisions are currently being run by temporary acting directors who lack the authority to make long-term strategic decisions.
This internal paralysis has severely damaged the CDC's relationship with state and local health departments. Local health officials rely on Atlanta for clear, consistent guidance, funding, and technical support. Instead, they have spent the last year receiving conflicting messages and dealing with sudden administrative shifts.
If Schwartz is confirmed, her first task will not be managing a global outbreak, but repairing the broken pipes of the agency's internal infrastructure. She will have to convince the remaining career staff that their work still matters, while proving to state health commissioners that the CDC can still be trusted as a reliable partner.
The hearing today is not a formality. It is a high-stakes test of whether the traditional public health system can find a way to work with an administration determined to rewrite the rules of medicine. Dr. Erica Schwartz’s answers will show whether she is the leader who can preserve the CDC's mission, or if she is simply the next executive destined to be ground up by the gears of Washington politics.
